Westfield Capital Management’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
RCM
Westfield Capital Management's NVAX Position: Q4 2021 in Review
Westfield Capital Management sold out of Novavax (NVAX) in Q4 2021, closing a stake of 238,400 shares — an estimated $49.4M sold.
Westfield Capital Management first reported a position in NVAX in Q2 2013 and held it in 4 quarters. The position peaked at $49.4M in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.
- Westfield Capital Management reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
- Westfield Capital Management sold 238,400 Novavax shares in Q4 2021, an estimated $49.4M.
- Westfield Capital Management first reported a position in Novavax in Q2 2013 and held it in 4 quarters.
- Westfield Capital Management's Novavax position peaked at $49.4M in Q3 2021.
- 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.
Based on Westfield Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.